| Status: Supported for use via the One Wales Medicines process | |
Arsenic trioxide in combination with all-trans retinoic acid can be made available within NHS Wales for the first line treatment of high-risk acute promyelocytic leukaemia, characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha gene, in adult patients unsuitable for anthracycline-based therapy. The risks and benefits of the off-label use of arsenic trioxide for this indication should be clearly stated and discussed with the patient to allow informed consent. At the latest review of this recommendation in September 2023, the decision by the One Wales Medicines Assessment Group was to retain the current advice with no changes required. Next review: this decision will be reviewed again after three years or earlier if new evidence becomes available. |
Darllen yn Gymraeg / Read in English
Beth benderfynodd Grŵp Asesu Meddyginiaethau Cymru'n Un?
Gellir defnyddio arsenig triocsid, a roddir mewn cyfuniad ag asid retinoic, i drin math prin o ganser y gwaed o'r enw lewcemia promyelocytic acíwt (APL). Dim ond os nad yw pobl yn gallu cael triniaethau sy'n cynnwys anthracyclines (math o gemotherapi) y gellir rhoi arsenig triocsid i drin APL risg uchel sy'n gysylltiedig â genyn diffygiol o'r enw Lewcemia Pro-Myelocytic/Retinoic-Acid-Receptor-alpha (PML/RARA).
Bydd arsenig triocsid ar gael i gleifion cymwys sydd wedi cofrestru gyda phractis meddyg teulu yng Nghymru, hyd yn oed os oes angen iddynt dderbyn eu triniaeth y tu allan i Gymru.
Nid yw arsenig triocsid wedi'i drwyddedu i drin APL risg uchel, felly os caiff ei ddefnyddio i drin APL risg uchel fe’i gelwir yn ddefnydd all-drwydded. Pan gaiff meddyginiaeth ei defnyddio yn “all-drwydded”, rhaid i'ch meddyg esbonio'n glir i chi y risgiau a'r manteision o gymryd y feddyginiaeth. Dylai eich meddyg roi gwybodaeth glir i chi, siarad â chi am eich opsiynau a gwrando'n ofalus ar eich barn a'ch pryderon. Darllenwch ein taflen wybodaeth i gleifion am ddefnydd di-drwydded ac all-drwydded o feddyginiaethau.
Mae Grŵp Asesu Meddyginiaethau Cymru'n Un ac AWTTC yn adolygu'r penderfyniad hwn yn rheolaidd i weld a oes unrhyw dystiolaeth newydd a allai effeithio ar y penderfyniad hwn.
I gael rhagor o wybodaeth am APL ewch i: Lewcemia promyelocytic acíwt - Blood Cancer UK
What did the One Wales Medicines Assessment Group decide?
Arsenic trioxide, given in combination with retinoic acid, can be used to treat a rare type of blood cancer called acute promyelocytic leukaemia (APL). Arsenic trioxide can only be given to treat high-risk APL that is associated with a faulty gene called Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RARA), if people are unable to receive treatments that contain anthracyclines (a form of chemotherapy).
Arsenic trioxide will be available to eligible patients who are registered with a GP practice in Wales, even if they need to receive their treatment outside Wales.
Arsenic trioxide is not licensed to treat high-risk APL, so using it to treat high-risk APL is called “off‑label” use. When a medicine is used “off-label”, your doctor must clearly explain to you the risks and benefits of taking the medicine. Your doctor should give you clear information, talk with you about your options and listen carefully to your views and concerns. Read our patient information leaflet about unlicensed and off-label use of medicines.
The One Wales Medicines Assessment Group and AWTTC review this decision regularly to see if there is any new evidence that may affect this decision.
For more information on APL visit the Blood Cancer UK website at: Acute promyelocytic leukaemia - Blood Cancer UK
Health boards will take responsibility for implementing One Wales Medicines Assessment Group decisions and ensuring that a process is in place for monitoring clinical outcomes.
Background: Acute promyelocytic leukaemia (APL) is a distinct subtype of acute myeloid leukaemia (AML) and presents clinically with coagulation disorders, which are associated with life threatening haemorrhages. Arsenic trioxide is recommended for use in adult patients with newly diagnosed low-to-intermediate risk APL by the National Institute for Health and Care Excellence (NICE). Treatment of high-risk APL (white blood cell count of >10 × 109/L) remains off-label and is currently supported by One Wales interim advice. Clinicians in Wales consider treatment to meet an unmet need and is a potentially curative option for a very small patient group.
Current One Wales Decision: The concentrate for solution for infusion formulation is supported for use for this indication.
Licence status: Arsenic trioxide is not currently licensed to treat high risk, front line APL in adults; its use in this indication is off-label. AWTTC is not aware of any plans to pursue marketing authorisation of arsenic trioxide for this indication at this time.
Guidelines: There have been no new relevant guidelines or relevant updates to existing guidelines identified.
Licensed alternative medicines or Health Technology Assessment advice for alternative medicines: The NICE appraisal [ID3864] of oral azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma was discontinued in December 2022 after the applicant company advised that marketing authorisation for this indication was no longer being pursued.
Effectiveness: A repeat literature search undertaken by AWTTC identified a randomised multicentre non-inferiority phase III study (Wang et al 2022) to compare the efficacy of all trans retinoic acid and arsenic trioxide (ATRA-ATO) and ATRA-ATO plus chemotherapy in newly diagnosed all-risk APL. In total 128 APL patients were assigned to receive ATRA-ATO for induction, consolidation, and maintenance or ATRA-ATO plus chemotherapy induction therapy followed by three cycles of consolidation therapy with ATRA-ATO plus chemotherapy and maintenance therapy with ATRA-ATO for 6–10 cycles. The trial was designed to evaluate the non-inferiority in disease free survival (DFS) after two years following induction therapy. DFS was defined as the time from haematological complete remission to either haematological or molecular relapse or death from APL. The primary end point was event-free survival (EFS) and DFS at 2 years. Secondary endpoints included overall survival (OS) at 2 years. Two-year DFS was 98% in the ATRA-ATO group and 97% in the ATRA-ATO plus chemotherapy group (P = 0.62). The percentage difference in DFS between the two groups was 1.4% (95% CI: 3.8–6.8). The lower limit of the 95% CI for the percentage difference in DFS was greater than the −10% non-inferiority margin, confirming non-inferiority. Of the 128 patients, 21 patients in the non-chemotherapy group and 19 patients in the chemotherapy group had high-risk APL. For high-risk patients, the 2-year DFS was 94% and 87% in the ATRA-ATO treatment regimen compared to ATRA-ATO plus chemotherapy, respectively (P = 0.52). The EFS and OS for high-risk APL patients were 85% and 85% in the non-chemotherapy group versus 78% and 83% in the chemotherapy group (P = 0.44 and 0.96, respectively). Complete remission was achieved in 90% of high-risk patients in the non-chemotherapy group versus 89% in the chemotherapy group.
Safety: In Wang et al 2022, ATRA-ATO was generally better tolerated than ATRA-ATO plus chemotherapy (all-risk patient groups). Most severe adverse events occurred during induction therapy. Grade 3–4 neutropenia and thrombocytopenia lasting more than 15 days occurred more commonly in the chemotherapy group than the non-chemotherapy group, although this did not reach statistical significance (45% versus 32%, P = 0.13). There was also a significantly higher proportion of patients experiencing Grade 3–4 cardiac toxicity in the chemotherapy group vs the non-chemotherapy group (12% versus 2%, P = 0.03).
Cost-effectiveness: No relevant cost-effectiveness analyses were identified in the repeat literature search.
Budget impact: The estimated eligible population reported in the original evidence status report was five patients per year in Wales. Since the last review in July 2021, AWTTC is aware of [CONFIDENTIAL DATA REMOVED]
Impact on health and social care services: No new impact data have been provided, though we consider the impact of this medicine to be minimal.
Patient outcome data: In Cardiff and Vale University Health Board [CONFIDENTIAL DATA REMOVED]. Data from the remaining health boards have not been provided.
Next review date: July 2026
References: a full reference list is available on request.
Disclaimer: This document includes evidence published since the last review or full assessment of this medicine for the indication under consideration. It does not replace the original full evidence status report. Any previous reviews and the original full evidence status report are available from this webpage in the document history section.
Care has been taken to ensure the information is accurate and complete at the time of publication. However, the All Wales Therapeutics and Toxicology Centre (AWTTC) do not make any guarantees to that effect. The information in this document is subject to review and may be updated or withdrawn at any time. AWTTC accept no liability in association with the use of its content. An Equality and Health Impact Assessment (EHIA) has been completed in relation to the One Wales policy and this found there to be a positive impact. Key actions have been identified and these can be found in the One Wales Policy EHIA document.
Information presented in this document can be reproduced using the following citation: All Wales Therapeutics & Toxicology Centre. Arsenic trioxide in combination with all-trans retinoic acid for the first-line treatment of high-risk acute promyelocytic leukaemia in adult patients unsuitable for anthracycline-based therapy (OW06). 2023
Copyright AWTTC 2023. All rights reserved.
Medicine details |
|
| Medicine name | arsenic trioxide |
| One Wales decision status | Supported for use via the One Wales Medicines process |
| Reference number | OW06 |
| Decision issue date | November 2016 |
| Date of last review | September 2023 |
| Review schedule | Every 3 years |